1. Home
  2. KLRS vs JRSH Comparison

KLRS vs JRSH Comparison

Compare KLRS & JRSH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • KLRS
  • JRSH
  • Stock Information
  • Founded
  • KLRS 2019
  • JRSH 2016
  • Country
  • KLRS United States
  • JRSH United States
  • Employees
  • KLRS N/A
  • JRSH N/A
  • Industry
  • KLRS Biotechnology: Biological Products (No Diagnostic Substances)
  • JRSH Apparel
  • Sector
  • KLRS Health Care
  • JRSH Consumer Discretionary
  • Exchange
  • KLRS Nasdaq
  • JRSH Nasdaq
  • Market Cap
  • KLRS 46.0M
  • JRSH 43.1M
  • IPO Year
  • KLRS N/A
  • JRSH 2018
  • Fundamental
  • Price
  • KLRS $6.31
  • JRSH $3.10
  • Analyst Decision
  • KLRS Strong Buy
  • JRSH Strong Buy
  • Analyst Count
  • KLRS 3
  • JRSH 1
  • Target Price
  • KLRS $21.50
  • JRSH $4.00
  • AVG Volume (30 Days)
  • KLRS 147.9K
  • JRSH 62.4K
  • Earning Date
  • KLRS 11-12-2025
  • JRSH 11-12-2025
  • Dividend Yield
  • KLRS N/A
  • JRSH 6.45%
  • EPS Growth
  • KLRS N/A
  • JRSH N/A
  • EPS
  • KLRS N/A
  • JRSH 0.05
  • Revenue
  • KLRS N/A
  • JRSH $146,234,005.00
  • Revenue This Year
  • KLRS N/A
  • JRSH $7.62
  • Revenue Next Year
  • KLRS N/A
  • JRSH $8.35
  • P/E Ratio
  • KLRS N/A
  • JRSH $62.47
  • Revenue Growth
  • KLRS N/A
  • JRSH 12.25
  • 52 Week Low
  • KLRS $2.14
  • JRSH $2.81
  • 52 Week High
  • KLRS $12.90
  • JRSH $4.17
  • Technical
  • Relative Strength Index (RSI)
  • KLRS 57.79
  • JRSH 38.33
  • Support Level
  • KLRS $6.04
  • JRSH $3.01
  • Resistance Level
  • KLRS $7.07
  • JRSH $3.20
  • Average True Range (ATR)
  • KLRS 0.66
  • JRSH 0.12
  • MACD
  • KLRS 0.08
  • JRSH -0.01
  • Stochastic Oscillator
  • KLRS 64.94
  • JRSH 30.26

About KLRS Kalaris Therapeutics Inc. Common Stock

Kalaris Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing therapeutics for prevalent retinal diseases. The company is developing TH103, a novel, clinical-stage anti-vascular endothelial growth factor (VEGF) drug, engineered to potentially provide longer-lasting and increased anti-VEGF activity in patients with exudative and neovascular retinal diseases. TH103 is a fully humanized recombinant fusion protein, functioning as a decoy receptor (a VEGF trap), leveraging salient molecular properties of the human body's native, highest affinity VEGF receptor 1.

About JRSH Jerash Holdings (US) Inc.

Jerash Holdings (US) Inc along with its subsidiaries, is a manufacturer and exporter of customized, ready-made sport and outerwear from knitted fabric from its production facilities in Jordan. The company manufactures for retailers, including Walmart, Costco, Sears, Hanes, Columbia, Land's End, VF Corporation, and Philip-Van Heusen, which owns brands such as The North Face, Nautica, Timberland, Wrangler, Lee, Jansport, Calvin Klein, Tommy Hilfiger, IZOD, and Speedo. It derives its revenue from the manufacturing and sales of outerwear in the United States. The company's product offering consists of jackets, polo shirts, crew neck shirts, pants, and shorts made from knitted fabric. Geographically, the company generates maximum revenue from the United States.

Share on Social Networks: